PT  - JOURNAL ARTICLE
AU  - OKADA, TAKURO
AU  - FUSHIMI, CHIHIRO
AU  - MATSUKI, TAKASHI
AU  - OKAMOTO, ISAKU
AU  - SATO, HIROKI
AU  - KONDO, TAKAHITO
AU  - TOKASHIKI, KUNIHIKO
AU  - KISHIDA, TAKUMA
AU  - ITO, TATSUYA
AU  - YAMASHITA, GAI
AU  - AIHARA, YUSUKE
AU  - HANYU, KENJI
AU  - KUSHIHASHI, YUKIOMI
AU  - MASUBUCHI, TATSUO
AU  - TADA, YUICHIRO
AU  - MIURA, KOUKI
AU  - HARADA, YUKI
AU  - MOMIYAMA, KAHO
AU  - YAMASHITA, TAKU
AU  - OMURA, GO
AU  - TAKAHASHI, HIDEAKI
AU  - ORIDATE, NOBUHIKO
AU  - TSUKAHARA, KIYOAKI
TI  - Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma
AID  - 10.21873/anticanres.15635
DP  - 2022 Mar 01
TA  - Anticancer Research
PG  - 1607--1613
VI  - 42
IP  - 3
4099  - http://ar.iiarjournals.org/content/42/3/1607.short
4100  - http://ar.iiarjournals.org/content/42/3/1607.full
SO  - Anticancer Res2022 Mar 01; 42
AB  - Background/Aim: There are no real-world comparative data of nivolumab doses of 3 mg/kg and 240 mg/body for recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN). We investigated the efficacy and safety of nivolumab in treating recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) at different doses using real-world data. Patients and Methods: R/M SCCHN patients who received nivolumab were divided into the 3 mg/kg and 240 mg/body groups and retrospectively examined for efficacy and safety. Results: A total of 199 patients (3 mg/kg and 240 mg/body, 88 and 111 patients, respectively) were included. The 3 mg/kg vs. 240 mg/body groups had similar overall response rates (15% vs. 25, p=0.15), disease control rates (46% vs. 57%, p=0.15), overall survival (9.5 months vs. 10.9 months), and progression-free survival (3.7 months vs. 3.8 months, p=0.95). The incidence of immune-related adverse events was also similar in both groups. Conclusion: In R/M SCCHN patients, nivolumab showed similar efficacy and safety at doses of 3 mg/kg and 240 mg/body.